Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This Chinese herbal formula is an investigational decoction developed by the Nanjing University of Traditional Chinese Medicine for the treatment of acute hemorrhagic stroke. It was evaluated as part of the "973" Project for Pathology of Traditional Chinese Medicine. The formula consists of eight specific herbs: Radix et Rhizoma Rhei Palmati (Rhubarb), Cornu Bubali (Buffalo Horn), Radix Paeoniae Rubra (Red Peony Root), Cortex Moutan Radicis (Tree Peony Root-bark), Radix Rehmanniae (Adhesive Rehmannia Root Tuber), Pheretima Aspergillum (Earthworm), Radix Notoginseng (Sanchi), and Rhizoma Acori Tatarinowii (Tatarinow Sweetflag Rhizome). It is designed to address the Traditional Chinese Medicine (TCM) patterns of "heat" and "blood stasis," aiming to reduce cerebral edema, promote hematoma absorption, and improve neurological recovery in patients following an intracerebral hemorrhage.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Chinese herbs formula (Nanjing University of Traditional Chinese Medicine).